Sidoti Estimates Prenetics Global’s Q1 Earnings (NASDAQ:PRE)

Prenetics Global Limited (NASDAQ:PRE) – Analysts at Sidoti decreased their Q1 2026 earnings per share (EPS) estimates for shares of Prenetics Global in a research report issued on Monday, March 30th. Sidoti analyst A. Hantman now forecasts that the company will post earnings of ($0.77) per share for the quarter, down from their previous estimate of ($0.74). The consensus estimate for Prenetics Global’s current full-year earnings is ($3.30) per share. Sidoti also issued estimates for Prenetics Global’s Q2 2026 earnings at ($0.85) EPS, Q3 2026 earnings at ($0.85) EPS, Q4 2026 earnings at ($1.09) EPS, FY2026 earnings at ($3.55) EPS, Q1 2027 earnings at ($0.12) EPS, Q2 2027 earnings at ($0.05) EPS, Q3 2027 earnings at $0.88 EPS, Q4 2027 earnings at $1.45 EPS and FY2027 earnings at $2.16 EPS.

A number of other equities analysts have also issued reports on PRE. Roth Mkm began coverage on shares of Prenetics Global in a research report on Wednesday, February 11th. They set a “buy” rating and a $36.00 price target for the company. Wall Street Zen downgraded shares of Prenetics Global from a “buy” rating to a “hold” rating in a report on Monday, February 16th. Lake Street Capital initiated coverage on shares of Prenetics Global in a research note on Monday, March 16th. They issued a “buy” rating and a $29.00 price objective on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Prenetics Global in a report on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $32.33.

Prenetics Global Stock Down 3.2%

Shares of NASDAQ PRE opened at $19.32 on Wednesday. The business’s 50 day moving average price is $19.34 and its 200 day moving average price is $16.17. The firm has a market cap of $325.16 million, a P/E ratio of -4.81 and a beta of 0.36. Prenetics Global has a 52 week low of $3.09 and a 52 week high of $23.63.

Prenetics Global (NASDAQ:PRE) last announced its quarterly earnings data on Wednesday, February 18th. The company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.22. Prenetics Global had a negative return on equity of 19.07% and a negative net margin of 61.33%.The business had revenue of $36.60 million for the quarter, compared to analyst estimates of $36.15 million.

Prenetics Global announced that its Board of Directors has initiated a share buyback program on Friday, March 6th that permits the company to buyback $40.00 million in outstanding shares. This buyback authorization permits the company to repurchase up to 15.8% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board believes its stock is undervalued.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Aberdeen Group plc purchased a new stake in Prenetics Global in the 3rd quarter worth approximately $979,000. UBS Group AG increased its holdings in shares of Prenetics Global by 581.9% during the 3rd quarter. UBS Group AG now owns 46,561 shares of the company’s stock valued at $619,000 after purchasing an additional 39,733 shares in the last quarter. Quadrature Capital Ltd purchased a new position in shares of Prenetics Global during the 4th quarter valued at approximately $468,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Prenetics Global in the 4th quarter valued at $307,000. Finally, Hudson Bay Capital Management LP acquired a new position in shares of Prenetics Global in the 4th quarter valued at $296,000. 25.01% of the stock is currently owned by hedge funds and other institutional investors.

Prenetics Global News Summary

Here are the key news stories impacting Prenetics Global this week:

• Positive Sentiment: Sidoti raised its FY2027 EPS forecast sharply to $2.16 (from $1.65), and upgraded several late‑2027 quarter estimates (Q4 2027 to $1.45, Q3 2027 to $0.88, Q1 2027 improved to -$0.12). This models a path to profitability in FY2027 and is a major positive catalyst for valuation and investor confidence.
• Positive Sentiment: Prenetics announced a strategic partnership with Superpower to integrate clinical‑grade supplementation with blood diagnostics — a consumer product/recurring‑revenue play that could expand addressable market and attach rates for testing services. Article Title
• Neutral Sentiment: Sidoti made a tiny technical lift to FY2026 (to -$3.55 from -$3.56) — effectively unchanged and still well below consensus (~-$3.30), so near‑term profitability remains a stretch per Sidoti’s model.
• Negative Sentiment: Sidoti trimmed several near‑term quarter estimates (Q1 2026 to -$0.77 from -$0.74, Q2 2026 to -$0.85 from -$0.79, Q3 2026 to -$0.85 from -$0.83, and Q2 2027 to -$0.05 from -$0.04). These downgrades suggest anticipated near‑term margin pressure or slower revenue recognition that could weigh on short‑term performance.

Prenetics Global Company Profile

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.